North America Home Infusion Therapy Market

The North America home infusion therapy market is expected to grow from US$ 10,954.08 million in 2022 to US$ 18,112.18 million by 2028. It is estimated to grow at a CAGR of 8.7% from 2022 to 2028.

Increasing Incidences of Chronic Disorders Coupled with Rising Geriatric Population is Driving North America Home Infusion Therapy Market

Chronic disorders such as cardiovascular, nutritional, and gastrointestinal disorders, rheumatoid arthritis, and neurological disorders affect the overall quality of life. According to the World Health Organization (WHO), over 50% of the global population is estimated to suffer from at least one chronic disease. The Centers for Disease Control and Prevention (CDC) stated that 6 out of 10 people in the US suffered from at least one chronic disease in 2019. According to the “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” a large-scale multinational study published in 2021, ~40% of 73,076 adults surveyed from 33 countries in the world were suffering from a functional gastrointestinal disorder (GFID). Age-related gastrointestinal problems are more common in the elderly population, aged 64 and above.

Cardiovascular diseases (CVDs), especially the cases associated with hectic lifestyles, are a significant cause of surging mortality. According to the International Diabetes Federation (IDF), 537 million people worldwide, aged 20–79, had diabetes in 2021, and the number is estimated to rise to 783 million by 2045. Additionally, diabetes was the cause of 6.7 million deaths worldwide in 2021. According to the Neurological Alliance, ~14.7 million neurological cases were registered in 2019, with at least 1 in 6 people suffering from 1 or more neurological conditions.

Aging can cause a consistent loss of physiological integrity, resulting in a reduction in functionality and an increased risk of mortality. The degradation of body function is a key risk factor for contracting the majority of chronic diseases, including diabetes, CVD, and neurological diseases, among elderly patients. According to the Global Ageing Survey 2019, the frequency of a person aged 65 or above is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every 6 inhabitants by 2025. As per the US Census Bureau, the number of Americans with age 65 and above is anticipated to double from 46 million in 2016 to over 98 million by 2060, and the share of the elderly population in the global population will increase from 15% to ~24% in the same period.    

North America Home Infusion Therapy Market Overview  

The North America home infusion therapy market is segmented into the US, Canada, and Mexico. The US held the largest share of the North America home infusion therapy market in 2021. The projected growth of the home infusion therapy market in North America is attributed to the factors such as the presence of leading market players and their product developments, the growing geriatric population, and rising prevalence of diseases and infections. The US holds a significant share of the North America home infusion therapy market. The requirement for home and specialty infusion therapy has increased across the US due to the high prevalence of infections, gastrointestinal diseases & disorders, multiple sclerosis, rheumatoid arthritis, cancer, hemophilia, dehydration, congestive heart failure, immune deficiencies, and neurological disorders. According to a study by National Home Infusion Association (NHIA), in 2019, home infusion and alternate site providers catered to more than 3 million patients in the US, representing a 300% increase since the last industry study in 2008. Furthermore, in 2020, NHIA also estimated that home and specialty infusion comprises over 900 providers serving 3.2 million patients annually in the country. Also, as per the Population Reference Bureau (2019), it is estimated that the geriatric population of the US is expected to grow from 52 million in 2018 to 95 million by 2060. Thus, the presence of leading market players, the growing geriatric population, and the rising prevalence of diseases and infections are expected to increase the demand for home infusion therapy in the coming years.  

North America Home Infusion Therapy Market Revenue and Forecast to 2028 (US$ Million)

North America Home Infusion Therapy Market Segmentation

The North America home infusion therapy market is segmented into product, application, route of administration and country.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held the largest market share in 2022.  

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held the largest share of the market in 2022.

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held the largest share of the market in 2022. 

Based on country, the North America home infusion therapy market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

B. Braun Melsungen AG; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; JMS Co Ltd; Eitan Medical Ltd; Terumo Corp are the leading companies operating in the North America home infusion therapy market. 

North America Home Infusion Therapy Market Strategic Insights

North America Home Infusion Therapy Market Segmentation Analysis

North America Home Infusion Therapy Market Report Highlights

North America Home Infusion Therapy Report Scope

North America Home Infusion Therapy Market Country and Regional Insights